DEA Marijuana Business Registration: Federal Rules for State-Licensed Operators
This hub tracks how Drug Enforcement Administration registration under the Controlled Substances Act could apply to state-licensed marijuana businesses. It covers the legal basis for registration, how it differs from state licensing, the link to Schedule III rescheduling, and the open question of how federal registration would treat states with both medical and recreational programs. In October 2026, Marijuana Moment reported that DEA will not approve marijuana businesses in states with dual medical and recreational licensing. We update this page as DEA, the Justice Department, Congress, and state regulators publish rules, guidance, and court decisions.

Executive summary
The DEA has told the cannabis industry that a federal registration path, if one opens, will not automatically cover businesses operating in states that license both medical and adult-use cannabis. Marijuana Moment reported the position on October 31, 2026, under the headline "DEA Refuses To Approve Marijuana Businesses In States That Allow Dual Medical And Recreational Licensing." This page covers the framework around that development. It does not attribute details the headline does not establish, so read the original report and any DEA document it cites alongside this page.
Federal registration matters because the Controlled Substances Act (CSA) requires anyone who manufactures, distributes or dispenses a scheduled substance to hold a DEA registration (21 U.S.C. § 822). No state-licensed cannabis operator holds one. Moving marijuana from Schedule I to Schedule III would not by itself change that. Rescheduling changes the schedule. It does not create a registration pathway for a state-licensed retail market, and it does not make a product FDA-approved.
The stakes are large. State-legal cannabis is a market of tens of billions of dollars a year, with multistate operators (MSOs) carrying heavy tax burdens under 280E. A registration regime that favored medical-only states such as Florida and Pennsylvania, or that forced operators to split medical and adult-use supply chains, would reshape licensing economics in California, Colorado, Michigan, Massachusetts, Illinois, New York and Ohio.
This page works through the question with a three-gate model (schedule, registration, product), the legal framework, state-by-state exposure and a decision calendar.
Why this matters
DEA registration policy decides whether rescheduling delivers tax relief and legal certainty to state-licensed operators or only to a narrow federal research and pharmaceutical channel. Four groups are affected.
Operators and investors
Under 26 U.S.C. § 280E, businesses "trafficking" in Schedule I or II substances cannot deduct ordinary business expenses. Schedule III removes that bar. Operators have long treated rescheduling as the single largest balance-sheet event available to them. If DEA registration eligibility depends on a state's licensing model, the 280E benefit and the registration question could diverge in ways the market has not priced.
Patients
Roughly 40 states and the District of Columbia have medical cannabis programs, and 24 states plus D.C. have adult-use markets. Patients in medical-only states could get formal federal recognition first. Patients in dual-licensed states could find their programs treated as a federal problem. That outcome would be perverse: those states hold the most mature medical infrastructure.
States and regulators
State regulators license cultivators, processors and retailers under state law. Federal registration, if it came, would add a second compliance layer: DEA security rules, recordkeeping, and ordering and inventory controls. Regulators in dual-licensed states would have to decide whether to restructure their programs to fit a federal template.
Federal agencies
The DEA, the Department of Justice, the FDA and the Department of Health and Human Services (HHS) each hold a piece of the process. The DEA registers handlers. The FDA decides what counts as an approved drug. HHS supplies the scientific scheduling recommendation. Friction among them is the structural reason this issue has dragged on.
Background and history
Federal cannabis registration has been an unresolved gap since the CSA took effect in 1971, and every modern reform effort has run into it. The timeline below runs from the statute's origin to the October 2026 news.
1970: the Controlled Substances Act
Congress enacted the CSA as Title II of the Comprehensive Drug Abuse Prevention and Control Act of 1970. Marijuana was placed in Schedule I under 21 U.S.C. § 812, pending a study by the Shafer Commission. The commission recommended decriminalizing personal possession in 1972. President Nixon ignored the recommendation, and the scheduling stayed.
1996–2012: states move first
California passed Proposition 215 in 1996, the first state medical cannabis law. Other states followed. In 2012, Colorado (Amendment 64) and Washington voters approved adult-use sales, producing the first state systems that licensed cultivation and retail for non-medical use. By then, state licensing had no federal registration counterpart.
2005: Gonzales v. Raich
In Gonzales v. Raich, 545 U.S. 1 (2005), the Supreme Court held that Congress could reach even intrastate, home-grown medical cannabis under the Commerce Clause. State legalization therefore never displaced federal law. It only shaped federal enforcement priorities.
2013–2018: the Cole Memo era
The Department of Justice's August 2013 Cole Memorandum set enforcement priorities such as preventing sales to minors and diversion to other states. It told prosecutors to defer to state regulation where it was robust. Attorney General Jeff Sessions rescinded the memo on January 4, 2018, leaving state-legal operators with no written federal assurance.
2014–present: the appropriations rider
Since December 2014, a congressional rider (Rohrabacher-Farr, later Joyce-Blumenauer) has barred DOJ from spending funds to prevent states from implementing their medical cannabis laws. Courts, including the Ninth Circuit in United States v. McIntosh (2016), applied it to limit prosecutions of compliant medical operators. The rider covers medical programs, not adult-use, and Congress must renew it each year. That medical/adult-use line is the one the October 2026 headline echoes.
2016–2022: the research registration bottleneck
DEA announced in 2016 that it would expand the number of registered marijuana growers for research beyond the University of Mississippi's NIDA-contracted farm. Applications sat for years. In 2020 the agency proposed a revised framework, and a 2022 law (the Medical Marijuana and Cannabidiol Research Expansion Act) directed DEA to process applications on a timeline. This is the only existing federal registration lane for marijuana growers, and it is a research lane.
2022–2024: the HHS review and the NPRM
In October 2022, President Biden directed HHS and the Attorney General to review marijuana's scheduling. HHS recommended Schedule III in August 2023. On May 21, 2024, DOJ and DEA published a notice of proposed rulemaking (NPRM) at 89 Fed. Reg. 44597 to move marijuana to Schedule III. The proposal did not address how state-licensed businesses would register, and it did not alter the CSA's treatment of adult-use markets.
2024–2025: the ALJ hearing stalls
DEA set an administrative hearing before an administrative law judge (ALJ) for January 2025. It was stayed amid disputes over participants and an interlocutory appeal, and the change of administration left the rulemaking frozen. The delay left operators, lenders and investors without a clear federal timetable.
December 2025: the executive order
President Trump signed an executive order in December 2025 directing the Attorney General to expedite completion of the Schedule III rulemaking and encouraging cannabidiol and medical marijuana research. The order did not itself reschedule marijuana. Final action still required the CSA's rulemaking steps.
November 2025–2026: the hemp backdrop
The federal funding law enacted in November 2025 redefined hemp to close the intoxicating-hemp-product channel, with a one-year delay that runs to November 2026. That change pushes more consumer demand toward licensed marijuana markets. It also puts a federal framework for those markets under pressure.
October 31, 2026: the dual-licensing report
Marijuana Moment reported that DEA refuses to approve marijuana businesses in states that allow dual medical and recreational licensing. The headline signals a registration policy that distinguishes between state licensing models. The specific vehicle (a rule, a hearing position, a letter or an official's statement) should be confirmed in the underlying article.
Key players
Five federal institutions and a handful of advocacy and industry groups shape the registration question, and their incentives differ.
Drug Enforcement Administration (DEA)
The DEA administers registration under 21 U.S.C. §§ 822–823 and 21 C.F.R. Part 1301. It decides whether registration is "consistent with the public interest" and with U.S. treaty obligations. DEA Administrator Terrance Cole has led the agency since mid-2025.
Department of Justice
The Attorney General holds scheduling authority and published the 2024 NPRM. DOJ also controls prosecutorial priorities and enforcement of the appropriations rider.
Food and Drug Administration and HHS
The FDA conducted the eight-factor scientific review underlying HHS's Schedule III recommendation. It also regulates drug approval. Under the Federal Food, Drug, and Cosmetic Act, state-licensed marijuana is not an FDA-approved drug, and that is a major obstacle to a registration framework for retail dispensaries.
Congress
Congress could bypass the agency process. The MORE Act would deschedule marijuana, the STATES Act would defer to state law, and SAFER Banking would address financial access. None has become law. Appropriations riders have been the only durable cannabis-specific federal statutory protection.
Industry and advocacy
- U.S. Cannabis Council and MSOs: They support rescheduling for the 280E relief but want a workable path for state-licensed businesses.
- NORML and the Marijuana Policy Project: They favor descheduling and have criticized Schedule III as incomplete. Their public statements stress that rescheduling alone leaves state markets exposed.
- Smart Approaches to Marijuana (SAM): It opposes rescheduling and commercial markets, and has pressed DEA to hold the line on state-licensed commerce.
- Pharmaceutical interests: They favor an FDA-approved pathway that keeps cannabis medicine within the drug-approval system.
Legal and regulatory framework
Registration is a statutory requirement, not a policy preference, and the CSA gives DEA wide discretion over who qualifies.
The registration mandate
Under 21 U.S.C. § 822, every person who manufactures, distributes or dispenses a controlled substance must register annually, with limited exceptions. 21 U.S.C. § 823 sets the standards for each registrant class. For Schedule I and II manufacturers, it requires findings on adequate competition and public interest. Under 21 U.S.C. § 824, DEA can deny, suspend or revoke registration, including when a registrant's state license is lost or the registrant has committed acts inconsistent with the public interest.
Implementing regulations
21 C.F.R. Part 1301 governs applications, security (§ 1301.71 and following), and recordkeeping. A Schedule III registrant must meet physical security, inventory and reporting standards that were not designed for retail cannabis. Many state-licensed operators would need to rebuild compliance programs to meet them.
Three gates, not one
CannIntel's analytic framework treats federal legality as three independent gates:
- Schedule gate: Where marijuana sits under 21 U.S.C. § 812. Schedule III would lift 280E, because 26 U.S.C. § 280E applies only to Schedule I and II substances.
- Registration gate: Whether a particular business can obtain a DEA registration under §§ 822–823. This is the gate the October 2026 headline concerns.
- Product gate: Whether the product is lawful under the FDCA. Even a Schedule III substance can be lawfully dispensed only if FDA-approved and prescribed, or within a research exception.
Clearing the first gate does not clear the others. A business can enjoy tax relief while still handling a product that is federally unapproved and unregistered. That mismatch is the core legal risk for operators.
Federalism and the rider
Under Raich, federal law preempts state authorization in the sense that conduct stays illegal federally. Yet the Joyce-Blumenauer rider limits DOJ spending against compliant medical programs. A registration framework that excluded dual-licensed states would sit awkwardly beside the rider, because the rider protects "medical" conduct in those states while adult-use remains unprotected. A DEA st
Frequently asked questions
What is DEA marijuana business registration?
It is the federal registration the Controlled Substances Act requires of anyone who manufactures, distributes, or dispenses a controlled substance (21 U.S.C. § 822; 21 CFR Part 1301). State-licensed marijuana businesses have generally not held DEA registrations because marijuana has been Schedule I, which permits registration only for narrow uses such as federally authorized research.
What did DEA reportedly decide about dual-licensing states?
Marijuana Moment reported on October 31, 2026 that DEA refuses to approve marijuana businesses in states that allow both medical and recreational licensing. We have not independently confirmed the details, such as the legal rationale or how long the position will last. This hub will be updated when DEA publishes official documents.
What is a dual medical and recreational licensing state?
It is a state that runs both a medical cannabis program and an adult-use (recreational) program, often under the same licensed businesses. Examples include California, Colorado, Michigan, and Massachusetts. The distinction matters federally because medical-only programs have different legal treatment than adult-use markets.
How is DEA registration different from a state cannabis license?
A state license authorizes a business to operate under state law. A DEA registration is federal permission to handle a controlled substance under the Controlled Substances Act. A state license does not protect a business from federal law, and a DEA registration would add federal requirements such as recordkeeping, security, and inspections.
How does Schedule III rescheduling relate to DEA registration?
HHS recommended moving marijuana to Schedule III in 2023, and DEA published a proposed rule in 2024. A 2025 executive order from President Trump directed the Justice Department to speed up the process. Schedule III drugs can be handled by DEA registrants, so rescheduling raises the question of how, or whether, state-licensed businesses would register.
Does rescheduling to Schedule III make state-licensed marijuana businesses federally legal?
No. Rescheduling changes a drug's classification, not automatically its legality outside the registration system. Schedule III substances still require DEA registration for manufacture and distribution, and FDA drug-approval and prescription rules would still apply. Whether state-licensed businesses could meet those requirements is a central open question.
Are medical marijuana programs treated differently from adult-use programs federally?
Yes, in one respect. Since 2014, a congressional appropriations rider has barred the Justice Department from using funds to interfere with state medical marijuana programs. It does not cover adult-use programs. That gap may help explain why regulators treat medical-only and dual-licensing states differently.
Does DEA currently register any marijuana growers?
DEA has registered marijuana growers only for federally authorized research. For decades the University of Mississippi was the sole federal supplier. DEA later said it would register additional growers, but those registrations cover research supply, not commercial state-licensed markets.
What should state-licensed operators do now?
Operators should keep complying with state licensing and track official DEA and Justice Department notices. They should also consult counsel on federal exposure, banking, and tax issues such as IRS Section 280E. A news report is not a substitute for a published rule or agency guidance.
Where can I find official DEA rules on marijuana registration?
Official actions appear in the Federal Register, on regulations.gov dockets, and in the DEA Diversion Control Division's registration pages. Registration rules are codified in 21 CFR Part 1301. Proposed and final rescheduling documents are published in the Federal Register.
The cannabis newsletter you forward to your team.
Federal policy, market data, grower alerts, and the one story that matters today. Sent every weekday at 7am. Free.
No spam. Unsubscribe with one click. 21+ only.